Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 15/20 | 0.52 |
| ▸ | PGR | P06401 | 13/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266646 | 0.85 | PGR (0.60) | NR3C2PGRNR3C1 | |
| SCHEMBL4264666 | 0.81 | PGR (0.56) | NR3C2PGRNR3C1AR | |
| SCHEMBL4260635 | 0.79 | NR3C2 (0.46) | NR3C2PGRNR3C1ARMMP12 | |
| SCHEMBL4262039 | 0.76 | NR3C2 (0.53) | NR3C2PGRNR3C1ARMMP12 | |
| SCHEMBL4265385 | 0.76 | NR3C2 (0.50) | NR3C2PGRNR3C1MMP12 | |
| SCHEMBL4257196 | 0.75 | NR3C2 (0.50) | NR3C2PGRNR3C1MMP12 | |
| SCHEMBL4263576 | 0.75 | NR3C2 (0.50) | NR3C2PGRNR3C1MMP12 | |
| SCHEMBL4264945 | 0.75 | PGR (0.46) | NR3C2PGRNR3C1ARMMP12 | |
| SCHEMBL4267401 | 0.75 | PGR (0.49) | NR3C2PGRNR3C1MMP12 | |
| SCHEMBL4258395 | 0.74 | NR3C2 (0.48) | NR3C2PGRNR3C1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | claimed |
| JP-2008508314-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1778242-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2007-05-02 | — | — | EP | claimed |
| WO-2006015259-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2006-02-09 | — | — | WO | claimed |
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | disclosed |
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | NR5A1, ESRRA, NR3C1 | NR3C2 7/4885PGR 46/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.